Special Issue "NMDA Receptor Antagonists for Treatment of CNS Disorders"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 December 2012)

Special Issue Editor

Guest Editor
Prof. Dr. Adeboye Adejare
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S. 43rd Street, Philadelphia, PA 19104, USA
Website: http://www.usciences.edu/academics/collegesDepts/pharmsci/Faculty/Adejare.aspx
E-Mail: a.adejar@usciences.edu
Interests: drug targeting; mechanisms of neurodegeneration; chemistry of fluoroaromatic compounds; pharmaceutical profiling

Special Issue Information

Dear Colleagues,

Glutamate receptors are known to play key roles in the CNS. Over-activity of these receptors which may be due to several factors including over-expression and higher levels of glutamate, has been linked to several CNS disorders. Glutamate receptors can broadly be divided into metabotropic and ionotropic. The ionotropic receptors have been further sub classified into three mainly based on agonists, namely, N-methyl-D- aspartic acid (NMDA), Kaininc acid and (alpha-amino-3-hydroxy-5-methyl-4- isoxazole-propionic acid) AMPA. While all these receptors are possible drug targets, the NMDA receptor has been particularly targeted for drug discovery efforts. These efforts have led to memantine, a USA FDA approved drug for treatment of Alzheimer’s disease. Other drugs acting at NMDA receptors are being examined for various disorders, from severe depression to drug abuse, to treatment of memory and learning issues in neurofibromatosis type 1 (NF1). The goal of this special issue is to examine current efforts in CNS drug discovery through this receptor.

Prof. Dr. Adeboye Adejare
Guest Editor

Keywords

  • glutamate
  • NMDA antagonist
  • CNS drug discovery
  • Alzheimer’s disease
  • neuropathic pain
  • drug addiction
  • memory and learning
  • ionotropic receptors

Published Papers (5 papers)

Pharmaceuticals 2013, 6(8), 1039-1054; doi:10.3390/ph6081039
Received: 29 May 2013; in revised form: 6 August 2013 / Accepted: 19 August 2013 / Published: 21 August 2013
Show/Hide Abstract | Download PDF Full-text (138 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2013, 6(4), 536-545; doi:10.3390/ph6040536
Received: 25 January 2013; in revised form: 9 April 2013 / Accepted: 9 April 2013 / Published: 12 April 2013
Show/Hide Abstract | Download PDF Full-text (1046 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Pharmaceuticals 2013, 6(4), 480-499; doi:10.3390/ph6040480
Received: 31 January 2013; in revised form: 27 March 2013 / Accepted: 27 March 2013 / Published: 3 April 2013
Show/Hide Abstract | Download PDF Full-text (237 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2013, 6(4), 469-479; doi:10.3390/ph6040469
Received: 25 December 2012; in revised form: 23 February 2013 / Accepted: 15 March 2013 / Published: 26 March 2013
Show/Hide Abstract | Download PDF Full-text (212 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2013, 6(2), 251-268; doi:10.3390/ph6020251
Received: 30 November 2012; in revised form: 29 January 2013 / Accepted: 29 January 2013 / Published: 6 February 2013
Show/Hide Abstract | Download PDF Full-text (304 KB) | View HTML Full-text | Download XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert